Literature DB >> 7957562

Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes.

D A Joyce1, D P Gibbons, P Green, J H Steer, M Feldmann, F M Brennan.   

Abstract

The biological activity of the pro-inflammatory cytokine, tumor necrosis factor (TNF)-alpha depends on the level of TNF-alpha itself, the expression of the p55 and p75 cell surface receptors for TNF on target cells and the concentrations of the natural inhibitors of TNF-alpha, the soluble p55 and p75 TNF receptors (TNF-R). Interleukin (IL)-10 and IL-4 are known to inhibit TNF-alpha production by monocytes. We, therefore, investigated the effects of IL-10 and IL-4 on the cell surface expression and release of TNF-R by human monocytes to determine whether these cytokines also indirectly modulated the biological activity of TNF-alpha. Exposure to IL-10 (1-10 U/ml) for 24 or 48 h increased soluble p75 TNF-R expression and concomitantly reduced surface expression of p75 TNF-R. Further, IL-1 alpha-stimulated production of TNF-alpha was diminished by IL-10 and only a small proportion of this TNF-alpha was bioactive, consistent with increased production of inhibitory soluble TNF-R. IL-10 also induced down-regulation of surface p55 TNF-R on monocytes, and increased release of soluble p55 TNF-R. However, the expression of soluble p55 TNF-R was much lower than soluble p75 TNF-R, indicating that it contributed less importantly to neutralization of TNF-alpha under these conditions. Like IL-10, IL-4 supressed the release of TNF-alpha by monocytes. In contrast to IL-10, however, IL-4 (0.1-10 ng/ml) supressed the release of soluble p75 TNF-R from monocytes in a dose-dependent manner. Release of soluble p55 TNF-R was also supressed by IL-4. IL-10, therefore, reduces the pro-inflammatory potential of TNF in three ways: by down-regulating surface TNF-R expression whilst increasing production of soluble TNF-R and inhibiting the release of TNF-alpha itself. This suggests that IL-10 may be useful in the treatment of diseases where overexpression of TNF-alpha occurs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957562     DOI: 10.1002/eji.1830241119

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

Review 3.  [Cytokines].

Authors:  M Feuchtenberger; C Kneitz; H-P Tony
Journal:  Z Rheumatol       Date:  2007-07       Impact factor: 1.372

4.  Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis.

Authors:  Ning Lu; Lihong Wang; Hailong Cao; Liping Liu; Luc Van Kaer; Mary K Washington; Michael J Rosen; Philip E Dubé; Keith T Wilson; Xiubao Ren; Xishan Hao; D Brent Polk; Fang Yan
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

Review 5.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 6.  Cytokine therapy in rheumatoid arthritis.

Authors:  J Hermann; M Walmsley; F M Brennan
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.

Authors:  T Kucharzik; N Lügering; M Adolf; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

8.  TNF-alpha and shear stress-induced large artery adaptations.

Authors:  C Keith Ozaki; Zhihua Jiang; Scott A Berceli
Journal:  J Surg Res       Date:  2007-06-15       Impact factor: 2.192

Review 9.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

Review 10.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.